Lexicon Pharmaceuticals, Inc.
LXRX
$2.32
-$0.02-0.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -29.03% | 123.12% | 60.24% | 1,255.21% | 1,504.83% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -29.03% | 123.12% | 60.24% | 1,255.21% | 1,504.83% |
| Cost of Revenue | 8.23% | -44.55% | 1.69% | -102.37% | -91.71% |
| Gross Profit | -32.79% | 175.09% | 75.58% | 207.28% | 187.06% |
| SG&A Expenses | -61.92% | -71.51% | -73.92% | -57.17% | -31.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -45.38% | -54.78% | -56.53% | -36.42% | -11.82% |
| Operating Income | 53.52% | 86.26% | 75.05% | 68.63% | 40.05% |
| Income Before Tax | 49.33% | 85.28% | 74.88% | 68.31% | 40.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 49.33% | 85.28% | 74.88% | 68.31% | 40.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 49.33% | 85.28% | 74.88% | 68.31% | 40.32% |
| EBIT | 53.52% | 86.26% | 75.05% | 68.63% | 40.05% |
| EBITDA | 53.70% | 86.53% | 75.30% | 68.85% | 40.18% |
| EPS Basic | 54.14% | 86.12% | 78.39% | 74.80% | 57.15% |
| Normalized Basic EPS | 56.70% | 86.02% | 78.26% | 74.98% | 57.20% |
| EPS Diluted | 54.14% | 86.12% | 78.39% | 74.80% | 57.15% |
| Normalized Diluted EPS | 56.70% | 86.02% | 78.26% | 74.98% | 57.20% |
| Average Basic Shares Outstanding | 8.03% | 6.77% | 13.52% | 24.74% | 38.46% |
| Average Diluted Shares Outstanding | 8.01% | 6.79% | 13.54% | 24.76% | 38.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |